Recently Prosensa provided reports on their financial results for the third quarter ending September 30, 2014 as well as an update on the regulatory plans and re-dosing for drisapersen, our lead exon-skipping drug candidate, and next steps for our follow-on exon skipping compounds for the treatment of Duchenne muscular dystrophy (DMD).